122 related articles for article (PubMed ID: 3492440)
1. Occurrence of autoantibodies to intermediate filament proteins in human visceral leishmaniasis and their induction by experimental polyclonal B-cell activation.
Böhme MW; Evans DA; Miles MA; Holborow EJ
Immunology; 1986 Dec; 59(4):583-8. PubMed ID: 3492440
[TBL] [Abstract][Full Text] [Related]
2. Autoantibody production by patients infected with Leishmania.
Argov S; Jaffe CL; Krupp M; Slor H; Shoenfeld Y
Clin Exp Immunol; 1989 May; 76(2):190-7. PubMed ID: 2788044
[TBL] [Abstract][Full Text] [Related]
3. Interferon-gamma and interleukin-4 production by human T cells recognizing Leishmania donovani antigens separated by SDS-PAGE.
Bahrenscheer J; Kemp M; Kurtzhals JA; Gachihi GS; Kharazmi A; Theander TG
APMIS; 1995 Feb; 103(2):131-9. PubMed ID: 7748537
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous leishmaniasis serodiagnosis by immunoperoxidase assay.
Halevy D; Sarov B; Sarov I; el-On J
Isr J Med Sci; 1990 Sep; 26(9):485-90. PubMed ID: 2228558
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
[TBL] [Abstract][Full Text] [Related]
6. Immuno stimulating glycophosphosphingolipid antigen from Leishmania donovani is recognized by visceral leishmaniasis patient sera.
Bhaumik SK; Singh MK; Karmakar S; De T
Mol Biochem Parasitol; 2008 Jun; 159(2):121-9. PubMed ID: 18405984
[TBL] [Abstract][Full Text] [Related]
7. Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis.
Garg R; Gupta SK; Tripathi P; Hajela K; Sundar S; Naik S; Dube A
Vaccine; 2006 Apr; 24(15):2900-9. PubMed ID: 16448729
[TBL] [Abstract][Full Text] [Related]
8. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
9. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
Rachamim N; Jaffe CL
J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215
[TBL] [Abstract][Full Text] [Related]
10. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
Narayan S; Bimal S; Singh SK; Gupta AK; Singh VP; Sinha PK; Das P
Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
[TBL] [Abstract][Full Text] [Related]
12. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
13. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
14. Leishmania donovani: identification of novel vaccine candidates using human reactive sera and cell lines.
Arora SK; Pal NS; Mujtaba S
Exp Parasitol; 2005 Mar; 109(3):163-70. PubMed ID: 15713447
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
Bhardwaj S; Vasishta RK; Arora SK
Exp Parasitol; 2009 Jan; 121(1):29-37. PubMed ID: 18983842
[TBL] [Abstract][Full Text] [Related]
16. Identification of new antigens in visceral leishmaniasis by expression cloning and immunoblotting with sera of kala-azar patients from Bihar, India.
Theinert SM; Basu R; Forgber M; Roy S; Sundar S; Walden P
Infect Immun; 2005 Oct; 73(10):7018-21. PubMed ID: 16177384
[TBL] [Abstract][Full Text] [Related]
17. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis.
Carvalho EM; Bacellar O; Brownell C; Regis T; Coffman RL; Reed SG
J Immunol; 1994 Jun; 152(12):5949-56. PubMed ID: 8207220
[TBL] [Abstract][Full Text] [Related]
18. Identification of amastigote-specific antigens of Leishmania donovani using kala-azar patient sera.
Gupta N; Goyal N; Bhatia N; Kamboj KK; Rastogi AK
Indian J Exp Biol; 2001 Jul; 39(7):623-8. PubMed ID: 12019753
[TBL] [Abstract][Full Text] [Related]
19. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
[TBL] [Abstract][Full Text] [Related]
20. Effect of immunization with lipid associated polysaccharide antigen and anti CD-2 antibodies on class II MHC expression and cellular immune response in BALB/C mice infected with Leishmania donovani.
Bimal S; Bagchi AK; Das V; Sinha PK; Lal CS; Ranjan A; Gupta AK; Kar SK
Indian J Exp Biol; 2001 Sep; 39(9):878-82. PubMed ID: 11831368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
